A Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis
Authors:
- Anita CsorbaACAnita Csorba
- Gábor KatonaGKGábor Katona
- Mária Budai-SzűcsMBMária Budai-Szűcs
- Diána Balogh-WeiserDiána Balogh-Weiser
- Péter MolnárPMPéter Molnár
- Erika MakaEMErika Maka
- Adrienn KazsokiAKAdrienn Kazsoki
- Márton VajnaMVMárton Vajna
- Romána ZelkóRomána Zelkó
- Zoltán Zsolt NagyZNZoltán Zsolt Nagy
- György T. BaloghGyörgy T. Balogh
Open Access
- 28 January 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1623
Abstract
Cystinosis is a low-prevalence lysosomal storage disease. The pathomechanism involves abnormal functioning of the cystinosine lysosomal cystine transporter (CTNS), causing intraliposomal accumulation of the amino acid cysteine disulfide, which crystallizes and deposits in several parts of the body. The most common ophthalmic complication of cystinosis is the deposition of “gold dust” cystine crystals on the cornea, which already occurs in infancy and leads to severe photosensitivity and dry eyes as it gradually progresses with age. In the specific treatment of cystinosis, preparations containing cysteamine (CYA) are used. The availability of commercialized eyedrops for the targeted treatment is scarce, and only Cystadrops® are commercially available with strong limitations. Thus, magistral CYA-containing compounded eyedrops (CYA-CED) could have a key role in patient care; however, a rationally designed comprehensive study on the commercialized and magistral products is still missing. This work aims to build up a comprehensive study about commercialized and magistral CYA eye drops, involving pharmacokinetic and physicochemical characterization (applying mucoadhesivity, rheology test, investigation of drug release, and parallel artificial membrane permeability assays), as well as ex vivo tests, well supported by statistical analysis.Keywords
This publication has 26 references indexed in Scilit:
- Effect of pH and penetration enhancers on cysteamine stability and trans-corneal transportEuropean Journal of Pharmaceutics and Biopharmaceutics, 2016
- Treatment of corneal cystine crystal accumulation in patients with cystinosisClinical Ophthalmology, 2014
- Nephropathic cystinosis: an international consensus documentNephrology Dialysis Transplantation, 2014
- The species- and site-specific acid–base properties of biological thiols and their homodisulfidesJournal of Pharmaceutical and Biomedical Analysis, 2014
- A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: The Cystadrops OCT-1 studyMolecular Genetics and Metabolism, 2014
- Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lensesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- In Vivo Confocal Microscopy and Anterior Segment Optical Coherence Tomography Analysis of the Cornea in Nephropathic CystinosisOphthalmology, 2009
- Carboxymethylcellulose Binds to Human Corneal Epithelial Cells and Is a Modulator of Corneal Epithelial Wound HealingInvestigative Ophthalmology & Visual Science, 2007
- pH‐Metric log P. Part 1. Difference Plots for Determining Ion‐Pair Octanol‐Water Partition Coefficients of Multiprotic SubstancesQuantitative Structure-Activity Relationships, 1992
- Corneal Toxicity Studies in Rabbits and Dogs with Hydroxyethyl Cellulose and Benzalkonium ChlorideToxicological Sciences, 1989